Pharvaris (NASDAQ: PHVS) presented safety data supporting the combined use of its deucrictibant immediate-release capsules with extended-release tablets at the Consortium of Independent Immunology Clinics Spring 2026 Conference held April 17-19 in Arlington, Texas.

The analysis demonstrated that combining a 40 mg deucrictibant extended-release tablet for prophylaxis with one or two 20 mg immediate-release capsules for breakthrough attacks shows adequate safety margins based on clinical and nonclinical data.

The company also referenced a post-hoc analysis from its CHAPTER-1 prophylaxis study that examined breakthrough attacks treated with icatibant, another bradykinin B2 receptor antagonist. The analysis showed comparable attack durations between placebo-icatibant and deucrictibant-icatibant treatment groups.

"These safety data, combined with the post-hoc efficacy analyses of mechanism-on-mechanism treatment of breakthrough attacks, provide evidence for the potential of the combined use of deucrictibant as a prophylactic treatment and as an on-demand medication," said Peng Lu, Chief Medical Officer of Pharvaris.

Deucrictibant is an oral bradykinin B2 receptor antagonist in development for hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. The drug has received orphan drug designation from the FDA, European Commission, and Swissmedic.

Pharvaris is preparing marketing authorization applications for the immediate-release formulation and conducting a Phase 3 study for the extended-release tablet, with topline data expected in the third quarter of 2026.